Entities / Company
Ocugen.
biopharmaceutical company
- Reports this week
- 1
- Active events
- 1
- Connections
- 22
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
-
Ocugen will manufacture and supply OCU400 to Roots Pharmaceutical, which has strong reach across the Middle East and North Africa.Some support1 report
-
The CEO of Ocugen sold a large number of company shares on October 13, 2026.Some support1 report
-
A US court of appeals issued a decision changing the materiality standard for Ocugen.Some support2 reports
One to three months ago
Gone quiet
No new reports in 90+ days-
Ocugen addressed unmet medical needs for Stargardt patients through recent announcements regarding their research in Europe.Some support1 report2 developments inside
-
Huma Qamar was appointed Chief Medical Officer at Ocugen.Some support2 reports
-
Ocugen is updating its Retina Scientific Advisory Board, while Peter K Kaiser holds chairs at Cleveland Clinic and Ophthalmic Consultants of Boston.Some support1 report
-
Ocugen announced a regional partnership for OCU400 in Korea.Some support1 report1 development inside
-
Ocugen secured exclusive Korean rights for OCU400, and FDA concurrence was granted, enabling BLA submission.Some support1 report
-
Ocugen filed a registration statement with the Securities and Exchange Commission on August 13, 2025.Some support1 report
-
Ocugen announced it will participate in the Biotech on Tap 2025 conference.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Ocugen this week
News at the entities that move Ocugen most-
FDA StructuralThe FDA approved a Skyrizi regimen for Crohn's disease, based on an AFFIRM trial led by UNC.Moves Ocugen
-
United States court of appeals StructuralA US court of appeals ruled that the federal ban on switchblades is unconstitutional.Moves Ocugen
-
Korea OperationalKorea-linked financial instruments contributed to market turnover on October 23, 2026.Moves Ocugen
-
Sell Mentioned togetherInsider sold shares of Nextdoor stock, as disclosed in an SEC filing on October 19, 2026.Moves Ocugen
-
company Shared contextSparta Group is seeking reinstatement to trading on the Exchange, with Nano equipment being used in e-waste processing.Moves Ocugen
Connections
The 7 strongest of 22, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Ocugen's clinical development and ability to conduct trials are fundamentally dependent on regulatory approvals and designations granted by the FDA.
-
United States court of appeals Structural
The United States court of appeals regulates Ocugen by reviewing securities litigation and changing materiality standards.
-
Huma Qamar Structural
Huma Qamar serves as the Chief Medical Officer at Ocugen.
-
Korea Operational
Ocugen is actively operating in the Korean market, securing exclusive rights and forming regional partnerships for its gene therapy.
-
Sell Mentioned together
The entities are co-mentioned in an article describing the CEO's sale of shares.
-
company Shared context
Ocugen is identified as a company operating within the general corporate environment.
-
Alena Kohušová Shared context
Both entities are mentioned within the context of the European Medicines Agency regulatory environment.
History
Events by the month they beganOctober 2026
4 events- Ocugen provided financial updates and shared its business outlook on October 22, 2026.
- Ocugen will manufacture and supply OCU400 to Roots Pharmaceutical, which has strong reach across the Middle East and North Africa.
- The CEO of Ocugen sold a large number of company shares on October 13, 2026.
- A US court of appeals issued a decision changing the materiality standard for Ocugen.
September 2026
1 eventJune 2026
7 events- Ocugen addressed unmet medical needs for Stargardt patients through recent announcements regarding their research in Europe.
- Huma Qamar was appointed Chief Medical Officer at Ocugen.
- Ocugen is updating its Retina Scientific Advisory Board, while Peter K Kaiser holds chairs at Cleveland Clinic and Ophthalmic Consultants of Boston.
- Ocugen announced a regional partnership for OCU400 in Korea.
- Ocugen secured exclusive Korean rights for OCU400, and FDA concurrence was granted, enabling BLA submission.
- Ocugen filed a registration statement with the Securities and Exchange Commission on August 13, 2025.
- Ocugen announced it will participate in the Biotech on Tap 2025 conference.